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Abstract
Antidepressant (AD) consumption has been steadily increasing in the last decade in most coun-
tries. The explanations suggested by researchers for this increment are still under scrutiny. This study
attempts to identify the determinants of AD consumption by exploiting small area variations from
Switzerland between 2003 and 2014. We observe that two specific drugs - Citalopram and Escitalo-
pram - within the Selective Serotonin Re-uptake Inhibitors (SSRI) category are mainly responsible for
the increasing trend in AD consumption. Socio-economic, demographic, cultural, and geographical
characteristics of the area are included in multiple regression models with random and fixed effects of
AD consumption per capita. While most of these factors contribute to explain cross-area variations
in AD use, they provide little explanation for the temporal trend in overall AD consumption. Con-
versely, we find that the time trend in AD consumption is explained at least partially by the density of
prescribing physicians. More precisely, generic AD turn out to be positively associated with adverse
local economic conditions, while branded AD are negatively associated with adverse economic con-
ditions and positively related to the presence of neurologists and psychiatrists in the area. This may
suggest that generic AD drugs are more likely prescribed in accordance to need, whereas branded AD
are more likely to respond to preferences and financial incentives affecting suppliers.
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1 Introduction
Antidepressant (AD) consumption increased steeply over the past decade in all OECD countries, dou-
bling between 2000 and 2013 (McCarthy, 2013). The growth is mainly due to an increasing use of Se-
lective Serotonin Re-uptake Inhibitors (SSRI), i.e. the most recent category of AD drugs (Mojtabai and
Olfson, 2014; Poluzzi et al., 2013; Guaiana et al., 2005; Barbui et al., 1999).
Several factors contributed to the increasing use of AD, but evidence is far from being conclusive
(Moore et al., 2009). Firstly, the increase in consumption might be partially explained by the growing
incidence of depression (Meijer et al., 2004). The World Health Organization (WHO) ranks depression as
the prime contributor to global disability and the major contributor to suicide deaths (estimated up to
800.000 annually) (WHO, 2017; Whiteford et al., 2013). According to the WHO, the prevalence of depres-
sion is highest among older adults (55-74 years) and the total number of people living with depression
increased by almost 20% between 2005 and 2015. Secondly, an explanation may be found in the recent
economic crisis, that has posed a severe shock to many developed economies threatening living stan-
dards and boosting unemployment and suicide rates (e.g. Barr et al., 2012; McInerney et al., 2013). Other
factors, such as lower prescription thresholds, off-label use (e.g. sleeping- and eating disorders, and
chronic conditions), and growing public acceptance of mental health treatments, may also have con-
tributed to the steep increment of AD consumption (Mojtabai, 2007). Lastly, recent US studies underline
the role played by the expansion of insurance coverage for prescription drugs and promotional activi-
ties by the pharmaceutical industry in stimulating AD consumption (Frank et al., 2005; Domino, 2012;
Shapiro, 2018; Avery et al., 2012).
The importance of unravelling the determinants of AD consumption lies primarily in the cost of
depression and its treatment for society. Stewart et al. (2003) estimate the cost of depression to employers
in the US to be about USD 31 billion, with total costs adding up to as much as USD 44 billion in 1990 and
USD 81 billion in 2000 (Greenberg et al., 1993, 2003). Similarly, Sobocki et al. (2006) estimate the cost of
depression in Europe to be EUR 118 billion in 2004.
Some authors argue that these estimates severely underestimate the true costs of depression since
many individuals go untreated or undiagnosed, and because it is difficult to estimate the costs of e.g.
depression-related absenteeism, presenteeism, and reduced lifetime earnings (Hirschfeld et al., 1997).
However, the persistence of high morbidity despite the increasing use of antidepressants suggests either
that AD treatment is ineffective or that a large share of depressed people goes untreated. To this end,
recent medical literature has questioned the efficacy of treating depression (only) with AD. Effective de-
pression treatments may reduce mortality by decreasing the risk of suicide and other depression-related
causes of death, such as accidents, heart diseases or strokes. Some researchers argue that the basis of
1
treating depression with AD, the so-called chemical imbalance theory, is incorrect and treatment there-
fore inefficacious (Kirsch et al., 2002; Healy, 2004). Others argue that psychotherapy is at least as good
as pharmacotherapy and should perhaps be preferred since it comes with less side-effects and more sta-
ble long-term effects; or they argue that at least the combination therapy should be favoured (Cuijpers
et al., 2014a; Steinert et al., 2014; Cuijpers et al., 2014b; Kamenov et al., 2017). The most recent studies
comparing AD and placebo in the acute treatment of major depressive disorder in children and ado-
lescents fail to provide clear evidence on the advantages of AD as compared to placebo (Cipriani et al.,
2016; Kirsch et al., 2008; Jakobsen et al., 2017; Fournier et al., 2010). Conversely, the review of economic
evaluations of depression treatment shows favourable evidence in terms of cost-effectiveness for newer
AD as compared to tricyclic AD (Barrett et al., 2005). However, given the pharmacological heterogeneity
of the compared medicines, it is difficult to obtain a clear answer regarding the efficacy question (Hale,
2003).
This article seeks to contribute to the literature on the determinants of time- and spatial patterns in
AD consumption. In particular, we exploit detailed information on product level wholesales of AD (active
ingredients and brand names) for a panel of 106 very small regions covering the whole Swiss territory for
12 years, between 2003 and 2014. This allows us to exploit how time and geographical variation in AD
consumption is related to changes in socio-economic conditions, cultural- and supply side factors such
as the density of prescribing doctors. Moreover, our data allows us to exploit differences across molecules
and types of product (generic vs. branded).
We believe that Switzerland provides an ideal setting to investigate the determinants of the stark in-
crease in AD consumption. Switzerland is a federation with remarkable heterogeneity in terms of institu-
tional, cultural and economic characteristics, and health care organization, which leads to considerable
variation in the utilization of drugs across regions. AD consumption is close to the OECD average and
has increased substantially in the last 15 years. Depression is the most common mental disorder, with
an estimated cost of 9 billion CHF annually (Baer et al., 2013; Tomonaga et al., 2013). Furthermore, con-
sumers virtually face no costs of healthcare, given complete obligatory insurance coverage, a relatively
low mandatory deductible, and small (10%) co-payments. On the supply side, prescribing physicians are
paid under a fee-for-service scheme and have practically no relevant restrictions on prescription prac-
tices. Lastly, Switzerland is home to the headquarters of several large pharmaceutical companies. This
implies that the country is at the forefront of developments in the drug industry but also potentially more
exposed to industry marketing pressure.
We find evidence of large small area variation in AD consumption that is related to socio-demographic
and geographical factors. However, none of these factors explains the sharp increase in AD consump-
tion in the last decade. Furthermore, we do not find evidence of a correlation with the recent economic
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crisis. Instead of increasing AD consumption with unemployment, as one might expect, we find a pos-
itive relationship with income. Furthermore, the increasing time trend in consumption is apparently
explained, at least partially, by the local health care supply. In particular, areas with higher physician
density show higher AD consumption, especially for neurologists and psychiatrists, and to some extent
general practitioners (GPs).
Some interesting differences arise also in our analysis at product level. More precisely, while con-
sumption of generic AD shows a positive association with unemployment and prescribing GPs, branded
AD consumption is positively associated with income and prescribing neurologists and psychiatrists.
These findings are confirmed by the analysis at detailed product level on the two main active ingredients
sold in Switzerland: Citalopram and Escitalopram. We find that generic Citalopram is positively associ-
ated with GP density and unemployment rates, whereas branded Escitalopram is positively related with
density of neurologists and psychiatrists.
Having excluded many alternative explanations for our results, a plausible explanation is that a high
concentration of physicians in an area facilitates the marketing effort of pharmaceutical companies. AD
producers concentrate their marketing efforts in these areas to exploit the network effects. Therefore,
physicians in these areas are more likely to be visited by pharmaceutical sales representatives and po-
tentially increase their prescription rate.
The remainder of the paper is structured as follows. The next section explains the institutional back-
ground and provides some insights about the distribution of antidepressant drugs in Switzerland. Sec-
tion 3 presents the data, while Section 4 describes the main determinants of AD consumption and set
the empirical model. The results are discussed in Section 5. Finally, Section 6 concludes.
2 The institutional setting
Switzerland is a confederation consisting of 26 cantons (states), each with considerable administrative
competences, and an overall population of about 8 million people. Although public health is largely a
responsibility of the individual cantons, certain aspects of health care are regulated at the federal level.
For example, the health care system is chiefly funded through mandatory private health insurance. The
community-rated insurance premium, decided by the insurer, has to be approved by the Federal Office
of Public Health (FOPH). Competing insurers provide a homogeneous insurance package and individu-
als can change insurance provider in November each year. Although the deductible can be voluntarily
increased up to CHF 2,500, the minimum deductible of CHF 300 is relatively low. Any surplus that the in-
surer may earn has to be paid back to their insured population. Moreover, risk-adjustment is ascertained
through contributions to a risk fund by those insurers with a lower than average disease risk among their
insured population. Supplementary insurance can complement the basic insurance to provide further
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coverage, for instance for drugs not covered by the basic insurance package.
Market admission of medicines is assessed by Swissmedic, the Swiss federal agency for therapeutic
products. After gaining access to the market, a medicine can be included in the so-called "Spezialitäten
Liste" or Positive Drug List (SL) as drafted by the FOPH. Medicines that are on this list get reimbursed
by the insurer.1 Virtually all active ingredients included in our analysis are on this list. This implies
that patients consuming AD, after they have used their deductible, only face a 10% co-payment for their
prescription, until the annual cap of 700 CHF is reached, after which the co-payment rate drops to zero.2
Antidepressant drugs in the ambulatory setting can be prescribed by GPs and specialists. Although
in practice any physician in Switzerland could prescribe AD, we identify neurologists, psychiatrists, and
GPs as the ones most likely to do so. Upon prescription, AD are distributed through community pharma-
cies and dispensing physicians. Cantons decide on the settlement of pharmacies and on the possibility
for physicians to dispense drugs directly to patients. Physicians are typically self-employed and insur-
ance companies are obliged to contract with any licensed medical practitioner, with limited exceptions if
patients subscribe to a HMO-type insurance plan. Physicians get remunerated based on a fee-for-service
scheme according to rates established by insurers and service providers, and controlled by the FOPH. If
fees are no longer considered to be appropriate ("sachgerecht"), the Federal Office can intervene and
impose a change. Therefore, physicians have little control over the price of their services, and mainly
influence their revenues through the supplied quantity of services.
The price of pharmaceutical drugs may differ depending on whether medicines are prescribed by
dispensing physicians or pharmacists, and is based on the ex-factory price as set by the FOPH. The retail
price is composed by the ex-factory price and a mark-up for the reimbursement of logistic and capital
costs associated with drug distribution.
3 Data
Data for the analysis were obtained from IMS Health Switzerland and include annual wholesales of an-
tidepressants at detailed geographical level (brick) for each product in the N06A class between 2003 and
2014.3 The brick is a geographical unit representing a pharmaceutical sales area. Typically, a brick ag-
gregates small rural municipalities, while bigger urban municipalities are split into more than one brick.
1The only exception to this is the canton of Appenzell Ausserhoden that has its own Positive Drug List. In practice, this list
contains only herbal medication. However, one can obtain medication in the surrounding cantons of Appenzell-Innerrhoden
and St. Gallen.
2Only if the prescription concerns a branded medicine for which a less expensive interchangeable generic is available the co-
payment rate is 20%, with a specific stop-loss amount of 933 CHF, after which the rate is again 0. The latter rule was introduced
in 2006.
3The Anatomic Therapeutic Chemical (ATC) classes are defined by the World Health Organization (WHO) and the European
Pharmaceutical Market Research Association (EUphMRA) according to the chemical mechanism behind the main active ingre-
dient of each substance. The N06A class is part of the anatomical group N, Nervous System, and comprises all antidepressants.
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There are 227 bricks, each of them comprising at least 5 pharmacies and an average population of about
35,000 inhabitants. To exploit important socio-economic information provided at higher geographical
level, we aggregate the brick level data to the Spatial Mobility Region (SMR) level. The SMR is a statistical
subdivision of Switzerland based on economic activity around an agglomeration hub, that divides the
country in 106 local labor markets.
AD consumption is measured in Defined Daily Doses (DDD) per 1,000 inhabitants per day (DID).4
This measure allows us to compare consumption data across different molecules, packages, and regions.
Our DID measure is calculated using WHO standard doses for each pharmaceutical product and addi-
tional demographic data from the Swiss Federal Statistical Office (FSO).5 Herbal AD (class N06A2) are
excluded from the analysis since standard doses for therapeutic purposes are not defined (see Table 1 for
the list of molecules included in the analysis).
We obtained data on unemployment, mortality, and morbidity (measured by hospital admissions)
from the Swiss Federal Statistical Office (FSO) for the years 2003–2014. Also, income data, based on
tax reports, were delivered by the Federal Tax Administration and range from 2003 to 2013. Data on
the number of physicians for different specializations were provided by the Swiss Medical Association
(FMH) for the years 2003–2014. Unfortunately, not all these data are at the same geographical level.
Unemployment and income data are defined at the municipality level, whereas mortality and morbidity
data are aggregated at the MedStat region level. The latter spatial concept (MedStat region) does not
directly match the SMR level. In order to aggregate all the information at the SMR level and thus allow
for panel data analysis, we use a matching procedure based on population weights.6
To account for the skewness of the Swiss income distribution, we consider a log-transformation of
income data. Furthermore, the detailed population data allow us to obtain the unemployed population
as a share of the working age population as well as the mortality and morbidity (hospitalization) rates per
10,000 inhabitants per region. In particular, we consider the most relevant causes of hospital admissions
related to AD consumption, i.e. F32 and F33.7 The former category refers to depressive episodes, whereas
the latter refers to recurrent depressive disorder.
4According to the definition of the WHO, a defined daily dose is the assumed average maintenance dose per day for a drug
used for its main indication in adults.
5We first calculate the number of daily doses contained in the packages (p) of each product or active ingredient (a). Then,
we multiply this number by the number of units sold (Qpai t ) of each package and product, for each area (i ) and year (t ), to find
the number of total doses. Finally, we aggregate the total doses at product level and divide by 365 days and by the number of
inhabitants times 1,000 as follows: D I Dai t =
∑
p
DDDpa×Qpai t
popi t
× 1,000365 .
6We consider census data available for the years 1990, 2000, and 2010 with a resolution of 100 meter per 100 meter (grid),
and interpolate the population data from 2000 to 2014. Then, a number of grid cells is uniquely assigned to each spatial con-
cept (municipality, SMR, or MedStat), which allows us to compute spatial population weights and reassign information among
spatial concepts.
7These causes are selected according to the ICD-10 classification of mental and behavioral disorders.
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3.1 Descriptive statistics
To provide some general descriptive information on overall AD consumption in Switzerland in com-
parison to the international context, we combine our data with data previously published by the OECD
(2015). Figure 1 shows AD consumption measured in DID in Switzerland and other OECD countries. The
average Swiss consumption increased markedly from 40 DID at the beginning of our period (2003) to 60
DID at the end of the period (2013). Although the consumption is still above the OECD average, there is
an apparent convergence toward the mean.
In Figure 2 we illustrate the geographical variability of AD consumption in Switzerland and the change
over time, between 2003 (top map) and 2014 (bottom map). Darker colors on the map represent higher
consumption. Consumption is generally more concentrated in Latin-language areas (French, Italian
and Romansch) and around urbanised areas. While consumption around cities remains high over time,
it shifted to northern and eastern German-speaking regions. The linguistic or cultural discrepancy be-
comes even more apparent in Figure A.1. Both Latin- and German-language areas see an increase in AD
consumption over time, but the magnitude of this change is bigger for German-speaking areas.
In order to get a deeper insight, we shortly explore antidepressant consumption by ATC classes. SSRI
and SNRI are the main contributors to the increase in AD consumption over time (see Figure 3). More-
over, the former class stands out accounting for more than 50% of total AD consumption. More precisely,
two active ingredients within the SSRI class are predominant: Citalopram and Escitalopram (Figure A.2).
The latter ingredient appears to be the main responsible for the increase in SSRI over time. Both Citalo-
pram and Escitalopram were originally marketed in Switzerland by Lundbeck under the brand names
Seropram and Cipralex respectively. Citalopram is now mainly sold as a generic drug, whereas Escitalo-
pram includes generics only from 2014, just after the expiration of the patent. Escitalopram, a reformu-
lation of Citalopram, was introduced in 2003, just before the expiration of Lundbeck’s patent on Citalo-
pram. Looking more in detail at these two active ingredients we see that branded Citalopram has been
gradually replaced by generic Citalopram (Figure 4). However, Escitalopram consumption has increased
steeply. This may suggest that Lundbeck has successfully replaced the old branded drug (Citalopram)
with the new active ingredient (Escitalopram), which has contributed substantially to the increase in
overall AD consumption over the examined period.
Table 2 shows summary statistics for the variables that we include in our analysis. It is worth not-
ing that the Swiss unemployment rate is on average well below 3% over the period of interest. Most
of the variation in unemployment as well as in income is between regions. As in almost all developed
economies, unemployment shows a steady decline before 2008 and an increase in 2009-2010 because of
the financial- and economic crisis that hit most of Europe and the Western world around that time (Fig-
ure A.3). However, even in the worst years the average unemployment rate only reached 4% with some
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variation across areas, especially across different language regions.
Furthermore, there is on average a little more than 2 neurologists and psychiatrists per 10,000 inhab-
itants, and a little less than 7 GPs. Table 2 shows the change of AD prescribing physicians in Switzerland
as a share of the general population. We see that neurologists and psychiatrists increase at a faster rate
than the population, whereas the number of GPs as a share of the population is more or less constant.
Even though, in principle, any physician in Switzerland could prescribe antidepressant drugs, neurolo-
gists and psychiatrists are the most likely to use them in their practice.
Figure 5 provides some evidence on the health status of the Swiss population with a focus on men-
tal health. The mortality rate is declining over time since the growth in the number of deaths is out-
paced by an increase in the population (top-right graph). Also, the rate of suicides is on average decreas-
ing, which may suggest that mental health is overall improving (top-left graph). However, we observe a
stark reduction in the number of psychiatric beds (bottom-right graph), which can be attributed to de-
institutionalisation of mental health care and to an increase in outpatient treatment through pharma-
cological therapy. The German-speaking areas are the most affected by this change. This phenomenon
could partially explain the remarkable increase in the rate of hospital admissions for depression (bottom-
left graph), a possible adverse consequence of the reduction in psychiatric beds. Note, in particular, that
only the most severe cases of depression get hospitalised. Hence, a sort of substitution effect between
cases in psychiatric hospitals and cases in standard hospital wards can be hypothesized. Nevertheless,
the general mental health status of the population has not deteriorated. Indeed, we observe a decline in
the prevalence of depression (bottom-left graph).
4 Empirical strategy
We propose a consumption function of AD, where variation is related to socio-economic, demographic
and cultural aspects, as well as the characteristics of local health care supply, and living conditions of the
population in the geographical area (SMR). More precisely, we specify the following ad hoc econometric
model of AD wholesales per capita in Spatial Mobility Region i at time t :
ADi t =β1Ei t +β2Di t +β3Ci +β4Si t +β5Gi +δt +γc +αi +²i t , (1)
where Ei t are time-varying controls for local economic conditions (unemployment rate and the nat-
ural log of net median income), Di t are time-varying socio-demographic characteristics of the local area
(age structure, gender distribution, share of foreigners, population density), Ci are cultural aspects (ap-
proximated by the language spoken), Si t represents characteristics of local health care supply (neurol-
ogists and psychiatrists and GPs density), Gi are time-invariant geographical characteristics (i.e., mean
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altitude), δt is a time fixed effect, γc a canton fixed effect, and ²i t an error term. Canton fixed effects
are included to take differences in mental health policy into account, which are set at cantonal level.
Moreover, we control for population density and altitude to proxy for the level of access to health care
services.8
Given the panel nature of our data, we estimate the parameters of interest using both fixed (FE) and
random effects (RE) models. Unlike the RE model, the FE model treats αi as a fixed effect that captures
all time-invariant characteristics. This should reduce the probability of omitted variable bias since the
RE assumption that the regressors are uncorrelated with the unobservable characteristics in bothαi and
²i t might be too restrictive. However, the relatively high level of aggregation of some variables and their
measurement procedure may increase the chances of measurement error, particularly for physicians,
hospital admissions, and mortality. Therefore, measurement error and lack of within variation in some
of the explanatory variables might introduce downward bias in the estimates because of a low signal to
noise ratio (Griliches and Hausman, 1986). Moreover, our model always includes canton and year FE
which capture much of the spatial variation in our data. Hence, it does not surprise that the Hausman
test (Hausman, 1978) often does not reject the null hypothesis that the preferred model is RE vs. the
alternative FE model.
As a robustness check, we include health outcomes and stationary physicians (excluding neurolo-
gists and psychiatrists) in the model. Stationary physicians are not expected to prescribe AD, since they
lack specialisation for such prescriptions. We are fully aware that including health outcomes and ad-
ditional physicians as explanatory variables leads to a higher degree of endogeneity (“bad controls” ac-
cording to Angrist and Pischke, 2008). However, these controls are only meant to verify whether the coef-
ficients on specialists and GPs are also a proxy for the health status of the population in an area. Similarly,
stationary specialists are added to the equation to verify whether the association between physicians and
AD consumption in some areas is driven by hospital concentration rather than increased prescriptions.
5 Results
Our empirical investigation starts from Table 3 which shows the results of regressing the full sample of AD
consumption on socio-economic, demographic, and health supply variables, as stated in Equation (1).
For descriptive purposes, column 1 shows the results from an OLS regression of AD consumption on our
economic variables (unemployment and income) and baseline controls (year and canton fixed effects
and geographic controls). It appears that unemployment and income are both positively correlated with
AD consumption. However, as we account for the other explanatory variables (column 2) much of this
8Some cantons allow direct dispensing of drugs by physicians in remote areas. Hence, geographical indicators should at
least partially account for heterogeneity in the provision of medication across areas.
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correlation disappears.
From column 3 onwards, taking the panel structure of our data into account, we show the results
from RE and FE models. As already mentioned, RE and FE estimates are very similar. Therefore, so we
avoid commenting differences that are small and not statically significant. Whereas OLS suggest a posi-
tive association between unemployment rates and AD consumption, the RE and FE estimates show the
opposite. The coefficient of unemployment is negative, although not statistically different from zero.
Conversely, the coefficient of income indicates an increase of almost 0.07 DID for a one percent increase
in income. All in all, our estimates do not show any relationship between adverse local economic condi-
tions and AD consumptions. If anything, it seems that AD consumption increases with income.
Regarding the socio-demographic variables, we observe a strong negative effect for both age cate-
gories - below 15, and from 15 to 65 - as compared to the category 65 and over. Such a result does not
match with the available information on depression incidence by age reported by the Swiss Health Ob-
servatory based on the Swiss Health Survey (Schuler et al., 2016). Indeed, this shows opposite evidence,
namely a lower incidence of depression among the elderly. AD consumption is also negatively related
with the share of foreigners and the share of German speakers in a region.
Particularly interesting is the positive relationship between the density of prescribing doctors in a
region (GPs and neurologists and psychiatrists) and AD consumption. In all models, the coefficient for
neurologists and psychiatrists density is large and statistically significant at conventional levels. In par-
ticular, an increase by one standard deviation in the number of neurologists is associated with an in-
crease of about 3 DID in AD consumption (RE and FE models). The association for prescribing GPs is
weaker but still positive with a coefficient of about 0.8. These results appear to be robust since the esti-
mated coefficients do not alter qualitatively upon addition of health outcomes or other (non-prescribing)
specialists (columns 4 and 6).
All estimates reported so far include year fixed effects, which capture a large share of the variation
in AD consumption in the period of interest. However, given the sizeable increase in AD consumption
over the years, it is particularly relevant to understand which of the variables included in Equation (1)
can explain such an increase. For this reason, in Table 4 we summarize the results from a series of RE
estimates where we only report the coefficient of a linear time trend. In the first column, AD consump-
tion is regressed only on time and canton fixed effects showing that consumption of AD in Switzerland
grows steadily by 1.8 DID per year. In the following columns we sequentially add our set of controls,
namely economic, socio-demographic, geographic and supply side variables (as previously specified).
Except for the supply side variables, the table clearly shows that none of the regressors is able to explain
the large increase in AD consumption over time. Indeed, only the inclusion of physicians in the regres-
sion (column 5) significantly alters the time trend coefficient (-18%). The fixed effects estimates show a
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similar pattern (not reported).
So far, we have considered the total AD consumption without distinguishing across products or
molecules. For this reason, in Figure 6 we separately investigate the determinants of AD consumption by
type. Contrary to the total AD consumption estimates reported in Table 3, we find that an increase in the
unemployment rate is associated with increasing consumption of generic AD. Moreover, the estimated
coefficient of income indicates a negative association with consumption. The estimates for branded
AD show the opposite: branded AD strongly increase with income and decrease when local economic
conditions worsen (i.e., higher unemployment). These results suggest that generic AD respond to ad-
verse economic conditions while the consumption of branded products is pro-cyclical and increases
with people’s wealth. As shown before, the increasing density of neurologists and psychiatrists is associ-
ated to increasing AD consumption, both for generics and branded AD. Regarding GPs, this relationship
is observed only for generics.
Finally, in Figure 7 we separately analyse the consumption of generic Citalopram and branded Esc-
italopram, the most consumed active ingredients in Switzerland in the period under investigation (see
Figure 4). The consumption of generic Citalopram is positively associated with unemployment and neg-
atively associated with income, like the consumption of generics in general. Again, higher GP density
goes hand in hand with a higher consumption of generic Citalopram, while neurologists and psychia-
trists are not associated with the consumption of this molecule. Conversely, branded Escitalopram is
strongly associated with the density of neurologists and psychiatrists in an area but does not show any
significant association with local economic conditions.
6 Discussion
The results of our analysis indicate that changes over time in socio-demographic and economic condi-
tions do not explain the increase in AD consumption, at least for AD in general. For generic AD, however,
the results suggest that consumption is indeed related to higher need, since adverse local economic con-
ditions go hand in hand with higher consumption. Conversely, the evidence on branded AD mirrors the
findings on AD in general, which are negatively associated with unemployment and positively associated
with income. This might suggest that generic AD are consumed on a need-basis, while branded AD are
prescribed as so-called "happy pills". The analysis on the most relevant AD product (Citalopram) - that
has gradually changed from mainly branded to predominantly generic - corroborates the finding that
generics are correlated with adverse local economic conditions.
We find some evidence that local health care supply is correlated with increasing AD prescriptions
in general, with heterogeneous effects according to drug categories. More precisely, the consumption
of branded AD is strongly and positively associated with the density of neurologists and psychiatrists.
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This evidence is confirmed when we focus on the consumption of a single product - the chiefly branded
Escitalopram, introduced on the Swiss market just before 2003. Conversely, generics in general and spe-
cific generic products (Citalopram) are associated with the density of prescribing GPs. This result can be
attributed to several factors. Plausibly, we can exclude unobservable factors since we control for a large
set of determinants, such as socio-economic characteristics of the regions, demographic and cultural
aspects, local health care supply and geographical factors, as well as canton- and time fixed effects. Our
results could be driven by competition in local health care supply. Since physicians are competing for pa-
tients, they would be more inclined to prescribe medications in order to lock patients into their practice.
Given the nature of the Swiss health care system this is not an unlikely scenario. Lastly, the concentra-
tion of physicians in an area may accommodate marketing efforts by pharmaceutical companies. Highly
concentrated areas may be more exposed to visits from sales representatives, gently inducing physicians
to prescribe more AD.
The main limitation of our analysis is the level of aggregation of our data. In order to identify the
causal effects one should preferably use individual data, but unfortunately such data are not available
yet. The main advantage of using our geographical level of analysis (SMR) is that economic activity can
be captured in a sensible way. This allows us, for example, to control for "cross-border-shopping" assum-
ing that people do not go and obtain medication in another SMR. This is a very reasonable assumption
because all AD get reimbursed by the compulsory basic health insurance. Therefore, it is plausible to
assume that data aggregation at SMR level will capture all the consumption within the region with neg-
ligible consumption externalities from other regions.9
In conclusion, we observe that AD consumption in Switzerland is strongly associated with local
health care supply, suggesting that demand is at least partially induced by the supply. This could be
due to the incentive structure of the Swiss Health Care system or ease of marketing effort towards physi-
cians, but both claims would require more detailed analysis of the data. A closer investigation of the
structure of incentives, in particular mark-ups and profit margins for both pharmaceutical companies
and physicians, would contribute to refine our evidence.
9We realise that this assumption is satisfied in some cases - e.g. in Ticino where the geographical barrier of the St. Gotthard
excludes this kind of behaviour - while in other cases it may be too crude. This brings us to the potential acquisition of data on
AD consumption across country borders. Note, however, that virtually all AD are included in the so-called "Spezialitätenliste"
or positive drug list from the Federal Office of Public Health (FOPH). Hence, all AD get reimbursed by the compulsory basic
health insurance. Unless someone opts for a very high deductible and hence incurs the costs for treatment out of pocket, it is
unlikely that people cross SMR borders to purchase cheaper medication. Moreover, opting for the highest deductible is quite
unlikely for people suffering from depression. Therefore, it is plausible to assume that data aggregation at SMR level will capture
all the consumption within the region with negligible consumption externalities from other regions.
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Figure 1: Antidepressant consumption in OECD countries and Switzerland in 2000 and 2013 (or nearest
year available).
Notes - Adapted from: OECD (2015) (http://dx.doi.org/10.1787/888933281342). This graph shows the consumption of
antidepressants in 28 OECD countries and Switzerland (the latter is not included in the OECD-28 average). Consumption is
expressed in defined daily doses per 1,000 people per day (DID). A defined daily dose is a standard daily maintenance dose for
an adult defined by the World Health Organisation (WHO). The OECD-28 average is 58 DID in 2013, and consumption varies
between 13 DID in Chile and 118 DID in Iceland. Antidepressant consumption in Switzerland is 60 DID in 2014, just above the
OECD-28 average.
†Data for 2000 or nearest year missing.
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Figure 2: Antidepressant consumption across Swiss areas (spatial mobility regions - SMR) in 2003 and
2014.
Notes - The maps are detailed at spatial mobility region level. Darker areas indicate higher antidepressant consumption per
1,000 inhabitants per day. Highly urbanized areas and French- and Italian speaking regions (West and South respectively) show
higher levels of AD consumption in 2003 (upper map). Compared to 2003, urbanized areas and German-speaking regions
(North and East) show the highest increase in AD consumption in 2014 (lower map).
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Figure 3: Antidepressant consumption in Switzerland between 2003 and 2014 - Total and by ATC classes.
Notes - This graph illustrates average antidepressant consumption in Defined Daily Doses (DDD) per 1,000 inhabitants per day
(DID) over time. Details are provided by Anatomical Therapeutical Class (ATC). Overall consumption increases by 20 DID, from
40 to 60, between 2003 and 2014. The main share consists of Selective Serotonin Reuptake Inhibitors (SSRI), a relatively new
ATC class (about 25% of total consumption in 2014). The other relatively new ATC class, Serotonin and Neurotonin Reuptake
Inhibitors (SNRI), represents a smaller share of total consumption. Other antidepressants, among which are the Tricyclic An-
tidepressants (TCA), account for about 17% in 2014. The increase in total consumption is mainly driven by the increase in
consumption of SSRI. Herbal AD (N06A2) have been excluded from the analysis since daily doses for this class are not defined.
Data source: IMS Health Switzerland.
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Figure 4: Consumption of generic and branded SSRI drugs (Citalopram and Escitalopram) over time
(2003-2014).
Notes - This graph shows trends in the consumption of generic and branded SSRI drugs (Citalopram and Escitalopram) orig-
inally introduced by Lundbeck. The decline in branded Citalopram mirrors to a large extent the increase in branded Esci-
talopram and generic Citalopram. In 2013, Lundbeck’s patent for Escitalopram expired and a generic version of Escitalopram
entered the market.
Data source: IMS Health Switzerland.
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Figure 5: Trends in suicides, mortality, depression hospitalisation, and beds in psychiatric hospitals
(2003-2014).
Notes - This figure summarises the mental health situation in Switzerland. In the top-left graph we see suicides (ICD10 cate-
gories X60-X84) per 10,000 inhabitants, which are declining over time. Assisted suicides are excluded from the figure since FSO
has stopped recording these data from 2009. The top-right graph shows the trend in general mortality (excluding suidides).
Although the mortality rate shows a decreasing trend, mortality in absolute numbers shows a slightly increasing trend. A net
increase in the population due to the influx of migrants is responsible for this discrepancy. The bottom-right graph depicts hos-
pitalisations for depression and its prevalence (ICD10 categories F32 and F33, respectively Depressive episodes and Recurrent
depressive disorders). Although the prevalence of depression has decreased over time, hospital admissions have increased.
This is probably a consequence of the reduction of beds in psychiatric hospitals, as suggested by bottom-left picture.
Data source: Federal Statistical Office and Global Burden of Disease Study 2016 Results.
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Figure 6: Coefficients plot from random effects estimates for branded and generic AD.
Notes - This figure shows estimated coefficients from a random effects regression of generic and branded AD on the full set of
regressors specified in Eq. (1). The estimates indicate that generic AD consumption is positively related with unemployment
and negatively with income, which contrasts the results for general AD consumption. This indicates that worse socio-economic
conditions may be a predictor of generic AD consumption. Conversely, branded AD consumption is negatively related to un-
employment and positively related to income. Also, the consumption of branded AD is positively related to some demographic
aspects such as the share of females, and negatively related to the share of young individuals (below 15 years) and adults (be-
tween 15 and 65). The estimates also show a positive relation between generic AD consumption and prescribing physicians.
Branded consumption on the other hand is strongly and positively associated with neurologists/psychiatrists. This evidence
may suggest that generics are more likely to be prescribed on need basis (worse economic conditions), whereas the demand
for branded AD is more prone to the influence of supply side factors, which points in the direction of supply-induced demand.
Reported confidence intervals are 95% using robust standard errors.
a Data have been normalised to 0 mean 0 and 1 standard deviation.
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Figure 7: Coefficients plot from random effects estimates for branded Escitalopram and generic Citalo-
pram.
This figure shows estimated coefficients from random effects regressions on the full set of regressors specified
in Eq. (1) for the most important generic (Citalopram) and branded (Escitalopram) AD products. Citalopram is
mostly generic, whereas Escitalopram is virtually only branded. We see that Citalopram consumption is positively
related to unemployment and negatively related to income. This is similar to the estimates for generic AD in gen-
eral (see Figure 6) and indicates that Citalopram is mainly prescribed in regions with worse economic outcomes.
Furthermore, the coefficient for GPs is positive and significant. The estimates for Escitalopram on the other hand
only show a positive and strongly significant effect for prescribing neurologists and psychiatrists and a significant
effect for females and those below 15. This is in accordance with the estimates previously reported for branded AD
(see Figure 6).
Reported confidence intervals are 95% using robust standard errors.
a Data have been normalised to 0 mean 0 and 1 standard deviation.
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Table 1: Molecules included in the analysis by antidepressant class (EphMRA ATC code).
N06A4 - SSRI CITALOPRAM ESCITALOPRAM FLUOXETINE FLUVOXAMINE PAROXE-
TINE SERTRALINE
N06A5 - SNRI DULOXETINE VENLAFAXINE
N06A9 - TCA
and others
AGOMELATINE AMITRIPTYLINE BUPROPION CLOMIPRAMINE DIBEN-
ZEPIN DOSULEPIN DOXEPIN IMIPRAMINE LOFEPRAMINE MAPROTI-
LINE MIANSERIN MIRTAZAPINE MOCLOBEMIDE NEFAZODONE NOR-
TRIPTYLINE OPIPRAMOL REBOXETINE TRAZODONE TRIMIPRAMINE
Notes - This table reports the molecules included in our analysis. The ATC classes N06A4 (Selective serotonin
re-uptake inhibitors - SSRI) and N06A5 (Serotonin norepinephrine re-uptake inhibitors - SNRI) represent the
two newest classes of AD, whereas N06A9 (tricyclic AD and others) mainly represents older antidepressants. The
N06A2 class (herbal AD) is excluded since defined daily doses are not calculated.
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Table 2: Summary statistics.
Dependent variables Mean St. dev. ∆(2003−2014) Minimum Maximum
DID 45.43 13.05 20.03 19.58 101.38
DID branded 26.49 7.77 -4.09 12.01 56.62
DID generic 18.94 8.97 24.12 1.16 58.60
DID Escitalopram 6.07 3.82 10.13 0.52 23.24
DID Citalopram 9.51 3.10 -0.18 3.76 33.46
Control variables
Unemployment 2.68 1.17 -0.23 0.51 6.86
Income 41,605.96 6,986.36 2,845.31 17,419.59 60,479.66
Females 50.46 0.85 -0.50 47.92 52.83
Population < 14 15.72 1.77 -2.32 10.03 20.82
Population 15-65 67.25 1.74 -0.11 60.69 71.55
Foreigners 18.70 7.18 3.69 3.65 40.95
German speaking 64.30 37.25 -0.00 1.58 96.77
Specialists 2.36 2.38 1.08 0.00 14.98
GPs 6.72 1.52 0.22 2.63 11.99
Hospital admissions 20.63 7.15 6.12 2.89 56.07
Mortality 80.36 15.08 -7.82 40.00 167.92
Altitude 871.69 502.40 -1.94 268.34 2,348.13
Population density 381.89 683.02 46.65 7.77 5,114.61
Notes - This table reports summary statistics for the variables included in our analysis. We see that the average
daily consumption of AD over the period 2003-2014 is 45 defined daily doses per 1,000 inhabitants. In some
region consumption amounts to more than 100 DID. Consumption of branded AD represents the largest share
of total consumption with 26 DID on average. Generics consumption is 19 DID on average and shows a rela-
tively higher within-area variation as compared to branded AD. Citalopram is the most important generic AD
with 9.5 DID on average, while branded Escitalopram accounts for 6 DID and exhibits higher within variation.
This is probably due to the relatively recent entrance of Escitalopram into the market (just before 2003) with
regional disparities in the speed of adoption of the new medication. Unemployment is on average below 3%
in the whole period (2003-2014). Most of unemployment and income variation is between regions. On aver-
age, median income is about 41,600 Swiss francs. The gender share is roughly the same between females and
males. About 16% of people are below 15 years of age, while the working age population (15-64) constitutes
the large majority of the population (about 67%). On average, almost 20% of the population is foreign, varying
from 4% to 41%, mostly between regions. The share of German speaking population is on average 64%, with
very little variation within regions over time. There is a little more than 2 neurologists and psychiatrists per
10,000 inhabitants, and a little less than 7 GPs. More than 20 inhabitants out of 10,000 is hospitalised for de-
pression, while 80 people out of 10,000 inhabitants die for any cause. Lastly, 15% of regions have an altitude
above 1,500 meters, and nearly 20% of regions has a population density of less than 50 inhabitants per km2.
aPer 10,000 inhabitants.
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Table 3: Estimates from OLS and panel regressions of total AD consumption per capita at spatial mobility
region level.
1 2 3 4 5 6
OLS OLS RE RE FE FE
Unemployment 3.514∗∗∗ 1.653∗∗∗ -.486 -.192 -.661 -.374
(.349) (.470) (.438) (.405) (.463) (.432)
Income 8.301∗∗∗ 5.612∗∗∗ 7.864∗ 7.744 7.879 6.956
(2.182) (2.044) (4.750) (5.021) (5.748) (5.836)
Females .469 1.253 1.071 .699 .675
(.403) (.793) (.759) (.985) (.938)
Population < 14 -.737∗∗∗ -1.407∗∗∗ -1.242∗∗ -1.228∗ -1.128∗
(.187) (.510) (.487) (.668) (.643)
Population 15-65 -.183 -1.119∗∗∗ -.919∗∗ -1.250∗∗∗ -1.074∗∗
(.150) (.384) (.359) (.462) (.436)
Foreigners -.183∗∗∗ -.364∗ -.396∗∗ -.676∗∗ -.646∗∗
(.0687) (.200) (.197) (.286) (.275)
German speaking -.0595∗∗∗ -.104∗∗∗ -.0973∗∗∗ 13.02 9.643
(.0133) (.0360) (.0338) (22.49) (22.52)
Specialists 5.054∗∗∗ 3.609∗∗∗ 2.778∗∗ 2.848∗∗ 2.286∗
(.379) (1.124) (1.148) (1.286) (1.261)
GPs 1.641∗∗∗ .774∗∗ .797∗∗ .640 .708∗
(.300) (.370) (.378) (.398) (.405)
Other specialists 1.336∗∗ 1.023
(.656) (.679)
Hospital admissions .0789∗∗∗ .0768∗∗∗
(.0260) (.0258)
Mortality .0643∗∗∗ .0618∗∗∗
(.0170) (.0157)
Year FE Yes Yes Yes Yes Yes Yes
Canton FE Yes Yes Yes Yes Yes Yes
Geographical indicators Yes Yes Yes Yes No No
Observations 1272 1272 1272 1272 1272 1272
Mean dep var 45.43 45.43 45.43 45.43 45.43 45.43
adj. R2 .639 .763 .832 .837
Within R2 .833 .839 .834 .840
Between R2 .686 .710 .235 .233
Overall R2 .726 .745 .166 .162
Notes - Estimates of the determinants of antidepressant consumption using data from IMS Health Switzerland. Estimates
are obtained using data aggregated at SMR level on total AD consumption. Although the OLS estimates in the first two
columns indicate a positive association between unemployment and AD consumption, this is not confirmed by the RE
and FE estimates (columns 3-5). Moreover, income is generally positively related to antidepressant consumption. There
is evidence that regions with a relatively higher share of young age categories and a higher share of foreigners or German
speakers consume a lower amount of AD. Neurologists and psychiatrists are positively associated with AD consumption.
The RE estimates in columns 3-5, and the FE estimates in columns 5-6 indicate that this is not due to a worse health status
of the population, nor to hospital concentration in these regions. A similar result is found for prescribing GPs.
Significance levels: ∗ p < 0.10, ∗∗ p < 0.05, ∗∗∗ p < 0.01. Standard errors (in parentheses) are robust.
aData have been normalised to 0 mean and 1 standard deviation.
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Table 4: Time trend coefficients from RE regressions of AD consumption
on an increasing number of regressors
1 2 3 4 5
Time trend 1.769∗∗∗ 1.677∗∗∗ 1.720∗∗∗ 1.715∗∗∗ 1.442∗∗∗
(.0669) (.0833) (.177) (.178) (.153)
E_i t No Yes Yes Yes Yes
D_i t No No Yes Yes Yes
G_i No No No Yes Yes
S_i t No No No No Yes
Canton FE Yes Yes Yes Yes Yes
Observations 1272 1272 1272 1272 1272
Within R2 .801 .808 .818 .818 .825
Between R2 .529 .511 .520 .527 .683
Overall R2 .603 .592 .601 .606 .722
Notes - This table shows random effects (RE) estimates of antidepressant consump-
tion in DID. In each column, a new group of regressors, as specified in Eq. (1), is
included. In the first column, AD consumption in regressed on time only to reveal
the linear time trend. The consumption of AD grows steadily by 1.8 DID per year.
In column 2, socio-economic determinants (Ei t ) are added to the regression. The
time trend proves to be very persistent, although it lowers slightly to 1.7 DID. Simi-
larly, adding demographic characteristics (Di t ) in column 3 does not alter the linear
time trend. Geographical controls (Gi t ) do not seem to explain the increase of AD
consumption over time neither (column 4). Instead the addition of physicians (Si t )
to the regression does alter the time trend, which decreases to 1.4 DID. This suggests
that prescribing physicians at least partially explain the increase in AD consumption
over time, which may in turn indicate that demand is at least to some extent by the
supply.
Significance levels: ∗ p < 0.10, ∗∗ p < 0.05, ∗∗∗ p < 0.01. Standard errors (in paren-
theses) are robust.
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A Appendix
Figure A.1: AD consumption by predominant language in the region.
Notes - This graph shows AD consumption distinguished by predominant language in the region. The time trend in German-
speaking regions is steeper than the time trend in Latin-speaking regions (French and Italian), although the level of consump-
tion in the latter regions is generally higher throughout the whole time period.
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Figure A.2: Consumption of SSRI drugs (therapeutic category N06A4) by active ingredient over time
(2003-2014).
Notes - This graph shows the consumption of SSRI antidepressant drugs by active ingredient over time. Citalopram accounts
for the largest share of SSRI consumption, and Escitalopram shows the highest increase over time. Both active ingredients are
originally marketed by the same pharmaceutical company (Lundbeck).
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Figure A.3: Unemployment by gender.
Notes - This graph shows the development of unemployment in Switzerland over time by gender. There is a surge in unem-
ployment from 2008 to 2009. This can be attributed to the economic and financial crisis. Before the crisis, the unemployment
rate for females is relatively higher than the rate for males. These figures have apparently swapped after the crisis since female
unemployment is generally lower than male unemployment.
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